Subtopic Deep Dive
HIV-Associated Cardiovascular Disease
Research Guide
What is HIV-Associated Cardiovascular Disease?
HIV-Associated Cardiovascular Disease (HIV-ACVD) refers to elevated risks of myocardial infarction, stroke, and heart failure in people living with HIV due to viral persistence, immune activation, antiretroviral therapy (ART) effects, and traditional risk factors.
Cohort studies show HIV patients face 1.5-2x higher myocardial infarction rates after adjusting for age, smoking, and dyslipidemia (Friis-Møller et al., 2003; Triant et al., 2007). Inflammatory biomarkers like IL-6, D-dimer, and sCD14 independently predict mortality in ART-treated individuals (Kuller et al., 2008; Sandler et al., 2011). Over 10 key papers from 2003-2016, cited >15,000 times total, quantify these risks using competing risk models (Lau et al., 2009).
Why It Matters
CVD now rivals AIDS as a cause of death in HIV cohorts, with trends showing cardiovascular events rising from 1999-2011 (Smith et al., 2014). Integrated care must address ART-induced dyslipidemia alongside immune activation (Friis-Møller et al., 2003; Catapano et al., 2016). Triant et al. (2007) reported 1,094 AMI cases per 100,000 HIV patients yearly versus 344 in non-HIV controls, driving guidelines for statin use in HIV (Gazzard, 2008). Kuller et al. (2008) linked IL-6/D-dimer to 5x mortality risk, informing trials targeting inflammation.
Key Research Challenges
Quantifying ART-Linked CVD Risk
Disentangling ART effects from traditional factors requires large cohorts adjusting for smoking and dyslipidemia. Friis-Møller et al. (2003) analyzed 23,468 patients, finding protease inhibitor exposure doubled MI risk. Competing risks from AIDS confound estimates (Lau et al., 2009).
Persistent Inflammation Prediction
IL-6, D-dimer, and sCD14 predict mortality post-ART, but miRNAs do not (Murray et al., 2015; Kuller et al., 2008). Sandler et al. (2011) showed sCD14 independently forecasts death in 1,000+ patients. Validating causal links to CVD events remains unresolved.
Competing Mortality Modeling
AIDS deaths compete with CVD, biasing hazard ratios without subdistribution models. Lau et al. (2009) outlined three regression approaches for epidemiologic data. Smith et al. (2014) applied these to D:A:D cohorts, revealing CVD rise.
Essential Papers
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study
Daniel D. Murray, Kazuo Suzuki, Matthew Law et al. · 2015 · PLoS ONE · 2.7K citations
No associations with mortality were found with any circulating miRNA studied. These results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major unde...
CD4+ Count–Guided Interruption of Antiretroviral Treatment
Wafaa El‐Sadr · 2006 · New England Journal of Medicine · 2.2K citations
BACKGROUND Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of...
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
Nina Friis‐Møller, Caroline Sabin · 2003 · New England Journal of Medicine · 1.7K citations
BACKGROUND It remains controversial whether exposure to combination antiretroviral treatment increases the risk of myocardial infarction. METHODS In this prospective observational study, we enrolle...
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
Virginia A. Triant, Hang Lee, Colleen Hadigan et al. · 2007 · The Journal of Clinical Endocrinology & Metabolism · 1.6K citations
Abstract Context: Metabolic changes and smoking are common among HIV patients and may confer increased cardiovascular risk. Objective: The aim of the study was to determine acute myocardial infarct...
Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection
Lewis H. Kuller, Russell P. Tracy, Waldo Belloso et al. · 2008 · PLoS Medicine · 1.6K citations
IL-6 and D-dimer were strongly related to all-cause mortality. Interrupting ART may further increase the risk of death by raising IL-6 and D-dimer levels. Therapies that reduce the inflammatory res...
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano, Ian Graham, Guy De Backer et al. · 2016 · Atherosclerosis · 1.6K citations
Competing Risk Regression Models for Epidemiologic Data
Bonnie Lau, Stephen R. Cole, Stephen J. Gange · 2009 · American Journal of Epidemiology · 1.3K citations
Competing events can preclude the event of interest from occurring in epidemiologic data and can be analyzed by using extensions of survival analysis methods. In this paper, the authors outline 3 r...
Reading Guide
Foundational Papers
Start with Friis-Møller et al. (2003) for ART-MI cohort baseline (23k patients); Triant et al. (2007) for AMI rate quantification; Kuller et al. (2008) for IL-6/D-dimer mortality predictors; Lau et al. (2009) for competing risks methods.
Recent Advances
Smith et al. (2014) tracks CVD death trends 1999-2011; Murray et al. (2015) tests miRNAs; Sandler et al. (2011) validates sCD14 as independent mortality marker.
Core Methods
Competing risk regressions (Lau et al., 2009); prospective cohorts like D:A:D (Friis-Møller 2003, Smith 2014); biomarker assays for IL-6, D-dimer, sCD14 (Kuller 2008, Sandler 2011).
How PapersFlow Helps You Research HIV-Associated Cardiovascular Disease
Discover & Search
Research Agent uses searchPapers and citationGraph on 'HIV myocardial infarction ART' to map 23,468-patient cohort from Friis-Møller et al. (2003), then exaSearch uncovers 50+ related works like Triant et al. (2007), while findSimilarPapers expands to inflammation biomarkers (Kuller et al., 2008).
Analyze & Verify
Analysis Agent applies readPaperContent to extract IL-6/D-dimer hazard ratios from Kuller et al. (2008), verifies via CoVe against raw cohort data, and runPythonAnalysis fits competing risk models from Lau et al. (2009) using pandas/NumPy on abstracted tables, with GRADE scoring evidence as high for mortality prediction.
Synthesize & Write
Synthesis Agent detects gaps in miRNA utility (Murray et al., 2015) versus sCD14 (Sandler et al., 2011), flags ART contradictions, and uses exportMermaid for biomarker-CVD pathways; Writing Agent employs latexEditText, latexSyncCitations for 10 foundational papers, and latexCompile for cohort review manuscripts.
Use Cases
"Reanalyze D:A:D cohort MI rates with Python competing risks"
Research Agent → searchPapers('D:A:D myocardial infarction') → Analysis Agent → runPythonAnalysis(pandas fit subdistribution hazards from Smith et al. 2014 tables) → matplotlib survival curves output.
"Write LaTeX review of HIV ART dyslipidemia guidelines"
Synthesis Agent → gap detection (Friis-Møller 2003 + Catapano 2016) → Writing Agent → latexEditText(draft) → latexSyncCitations(10 papers) → latexCompile(PDF with integrated figures).
"Find GitHub code for HIV biomarker competing risks analysis"
Research Agent → paperExtractUrls(Lau 2009) → paperFindGithubRepo → githubRepoInspect(R code for subdistribution models) → runPythonAnalysis(port to pandas sandbox).
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'HIV CVD biomarkers', structures report with GRADE tables from Kuller (2008)/Sandler (2011), and CoVe verifies risks. DeepScan's 7-steps analyze Friis-Møller (2003) cohorts with runPythonAnalysis checkpoints on adjusted HRs. Theorizer generates hypotheses linking sCD14 to ART dyslipidemia from gap detection across Triant (2007) and guidelines.
Frequently Asked Questions
What defines HIV-Associated Cardiovascular Disease?
Elevated MI, stroke, heart failure risks in HIV due to ART, inflammation, traditional factors (Friis-Møller et al., 2003; Triant et al., 2007).
What methods quantify HIV-CVD risks?
Prospective cohorts with competing risk regression adjust for confounders; Lau et al. (2009) detail subdistribution hazards, applied in D:A:D (Smith et al., 2014).
What are key papers on HIV-ACVD?
Friis-Møller et al. (2003, 1665 cites) links ART to MI; Triant et al. (2007, 1602 cites) shows 3x AMI rates; Kuller et al. (2008, 1586 cites) ties IL-6/D-dimer to mortality.
What open problems exist in HIV-ACVD?
miRNAs fail as predictors unlike sCD14/IL-6 (Murray et al., 2015; Sandler et al., 2011); causal inflammation interventions unproven despite mortality links (Kuller et al., 2008).
Research HIV-related health complications and treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HIV-Associated Cardiovascular Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers